Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: Amgen Inc. vs Apellis Pharmaceuticals, Inc.

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Amgen Inc. and Apellis Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Amgen, a biotech giant, has consistently invested heavily in SG&A, with a notable increase of approximately 31% from 2014 to 2023. This reflects its robust market presence and strategic investments in marketing and administration. In contrast, Apellis Pharmaceuticals, a relatively newer player, has seen a staggering increase in SG&A expenses, skyrocketing by over 17,000% during the same period. This dramatic rise underscores Apellis's aggressive expansion and market penetration efforts. As these companies navigate the evolving pharmaceutical landscape, their SG&A strategies offer valuable insights into their growth trajectories and competitive positioning.